OQROSign up free
Insider trade

Supernus Pharmaceuticals, Inc. (SUPN): CEO sold ~$1.09M

Jack A. Khattar, CEO at Supernus Pharmaceuticals, Inc., sold ~$1.09M of Supernus Pharmaceuticals, Inc. shares.

~$1.09M
Approx. value · 24K sh @ $45.12
1.09M
Holds after · shares reported
Traded
Aug 28, 2025
Filed
Aug 29, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Aug 6, 2025Insider · 1 personInsiders: 3 sales (~$5.9M)
  2. Aug 14, 2025Insider · 2 peopleInsiders: 2 sales (~$542K)
  3. Aug 22, 2025Insider · 3 peopleInsiders: 3 sales (~$655K)
  4. Aug 25, 2025Insider · 3 peopleInsiders: 3 sales (~$713K)
  5. Aug 27, 2025Insider · 2 peopleInsiders: 2 sales (~$641K)
  6. Aug 28, 2025 · this disclosureInsiderCEO sold ~$1.09M of SUPN shares in the open market

What came next

  1. Sep 5, 2025InsiderCEO sold ~$2.56M of SUPN shares in the open market
  2. Sep 8, 2025InsiderCEO sold ~$293K of SUPN shares in the open market
  3. Sep 12, 2025InsiderOfficer sold ~$229K of SUPN shares in the open market
  4. Sep 22, 2025InsiderCEO sold ~$780K of SUPN shares in the open market
  5. Sep 23, 2025InsiderCEO sold ~$1.39M of SUPN shares in the open market
  6. Sep 29, 2025InsiderCEO sold ~$491K of SUPN shares in the open market
  7. Oct 9, 2025CongressDisclosed partial sale of SUPN — reported range $1,001 - $15,000
  8. Oct 21, 2025Company filing · Form 8-K · ResultsReported its results
  9. Nov 4, 2025Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Supernus Pharmaceuticals, Inc.

OQRO holds no insider, Congress, fund or contract record for Supernus Pharmaceuticals, Inc. dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SUPN page.

Other recent filings by Jack A. Khattar, President, CEO

The full history of Jack A. Khattar, President, CEO is on the profile page.

How this filing works

Explore the data

Other disclosures at Supernus Pharmaceuticals, Inc.

Everything OQRO holds on this company is on its SUPN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Sign up freeAlready have an account? Log in

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data